To expand our understanding of C5 inhibitor treatment outcomes for these patients, the current study also provides a comprehensive real-world assessment of clinically important condition-related HRU among patients with PNH post-treatment with eculizumab or ravulizumab. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.